Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13635958 | 0.79 | ESR1 (0.52) | ESR1ESR2THRATHRBNPC1 | |
| SCHEMBL18812301 | 0.71 | ESR1 (0.44) | ESR1THRATHRB | |
| SCHEMBL16240889 | 0.71 | ESR1 (0.56) | ESR1ESR2THRATHRBNPC1 | |
| SCHEMBL24038030 | 0.71 | ESR1 (0.47) | ESR1ESR2THRATHRBNPC1 | |
| SCHEMBL14670707 | 0.70 | ESR1 (0.50) | ESR1THRATHRBNPC1HPGD | |
| SCHEMBL6685103 | 0.69 | ESR1 (0.74) | ESR1ESR2THRATHRBTDP1 | |
| SCHEMBL13233319 | 0.69 | ESR1 (0.54) | ESR1ESR2THRATHRBHPGD | |
| SCHEMBL15706822 | 0.66 | ESR1 (0.61) | ESR1ESR2THRATHRBTDP1 | |
| SCHEMBL19772887 | 0.65 | ESR1 (0.54) | ESR1ESR2THRATHRBMEN1 | |
| SCHEMBL13596293 | 0.64 | ESR1 (0.48) | ESR1ESR2THRATHRBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392421-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2019-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392421-B2 | Cytotoxic peptides and conjugates thereof | CD47, NGLY1, VIP | ESR1 3967/4885ESR2 3566/4885THRA 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.